Want to see MIRM full AI Analyst Report?
MIRM Stock Chart & Stats
$97.95
-$0.27(-0.64%)
At close: 4:00 PM EST
$97.95
-$0.27(-0.64%)
Day’s Range― - ―
52-Week Range$50.25 - $130.00
Previous CloseN/A
Volume92.82K
Average Volume (3M)947.28K
Market Cap
$7.79B
Enterprise Value$5.12B
Total Cash (Recent Filing)$386.26M
Total Debt (Recent Filing)$323.78M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Jul 30, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.61
Shares Outstanding60,981,228
10 Day Avg. Volume1,124,974
30 Day Avg. Volume947,280
Financial Highlights & Ratios
PEG Ratio2.25
Price to Book (P/B)12.60
Price to Sales (P/S)7.61
P/FCF Ratio72.26
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue8.99
Enterprise Value/Gross Profit11.05
Enterprise Value/Ebitda-6.73
Forecast
1Y Price Target
$147.00Price Target Upside50.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-15.65
Revenue Forecast (FY)$674.52M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & GuidanceSustained high-single-digit to double-digit product sales growth and an upward guidance revision signal durable commercial traction. Consistent top-line expansion improves the company’s ability to fund R&D and commercialization spending, supporting a path to operating cash flow breakeven and later profitability.
Strong Unit EconomicsVery high gross margins and mid‑50% cash contribution margins indicate robust product-level economics that can sustainably fund fixed selling and R&D costs as volumes scale. Favorable unit economics create durable operating leverage once one-time charges and elevated R&D normalize.
Near-Term Regulatory/BD CatalystA partnered NDA with priority review and a defined PDUFA creates a clear, structural catalyst that could diversify revenue beyond current liver indications. If approved and launched, the asset (estimated peak $200M+) materially broadens the addressable market and supports long‑term commercial scale.
Bears Say
Renewed Cash BurnA return to negative trailing‑twelve‑month operating cash flow despite product sales growth signals funding pressure. Persistent cash burn forces reliance on financing or asset sales, reducing strategic optionality and increasing execution risk if commercial ramps slow or approvals are delayed.
Elevated Leverage & Financing ComplexityA materially higher leverage profile and recent long‑dated convertible note issuance constrain financial flexibility. Complex conversion and redemption mechanics increase potential dilution and creditor protections, making capital structure outcomes sensitive to share price and operational execution over the medium term.
Acquisition-Related One-Time ChargesA very large acquisition-driven operating charge inflates reported losses and obscures core operating performance. Such one-time costs can delay GAAP profitability, distract management on integration execution, and raise questions about true recurring operating margins until post‑integration normalization.
Mirum Pharmaceuticals News
MIRM FAQ
What was Mirum Pharmaceuticals’s price range in the past 12 months?
Mirum Pharmaceuticals lowest stock price was $50.25 and its highest was $130.00 in the past 12 months.
What is Mirum Pharmaceuticals’s market cap?
Mirum Pharmaceuticals’s market cap is $7.79B.
When is Mirum Pharmaceuticals’s upcoming earnings report date?
Mirum Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 19 days.
How were Mirum Pharmaceuticals’s earnings last quarter?
Mirum Pharmaceuticals released its earnings results on May 06, 2026. The company reported -$13.43 earnings per share for the quarter, missing the consensus estimate of -$0.365 by -$13.065.
Is Mirum Pharmaceuticals overvalued?
According to Wall Street analysts Mirum Pharmaceuticals’s price is currently Undervalued.
Does Mirum Pharmaceuticals pay dividends?
Mirum Pharmaceuticals does not currently pay dividends.
What is Mirum Pharmaceuticals’s EPS estimate?
Mirum Pharmaceuticals’s EPS estimate is -0.73.
How many shares outstanding does Mirum Pharmaceuticals have?
Mirum Pharmaceuticals has 60,981,228 shares outstanding.
What happened to Mirum Pharmaceuticals’s price movement after its last earnings report?
Mirum Pharmaceuticals reported an EPS of -$13.43 in its last earnings report, missing expectations of -$0.365. Following the earnings report the stock price went down -6.495%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals?
Currently, no hedge funds are holding shares in MIRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mirum Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$147.00 (50.08% Upside)
$147.00 (50.08% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 576.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
138.87%
12-Months-Change
Fundamentals
Return on Equity
-289.33%
Trailing 12-Months
Asset Growth
29.07%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
MIRM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and meaningful pipeline and BD progress: solid Q1 sales growth (~42.9% YoY), an upward revision to full-year guidance, funded R&D investments, prioritized near-term regulatory catalysts (including a PDUFA on September 26, 2026), and a plan to scale the commercial team. These positives are tempered by a very large, one-time operating expense tied to the Bluejay acquisition that drove an unusually high quarterly operating charge ($761M of $949M), minimal Q1 operating cash flow (~$2M), elevated R&D spend, and remaining data and market-size uncertainties for some pipeline assets (e.g., FOP patient counts and certain subgroup signals in hepatitis delta). Management expects operating cash flow positivity next year and GAAP profitability by 2028, indicating confidence in the business model despite near-term accounting and investment-driven headwinds.View all MIRM earnings summariesMIRM Stock 12 Month Forecast
Average Price Target
$147.00
▲(50.08% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Catalyst Pharma
―
Ultragenyx Pharmaceutical
―
ImmunityBio
―
―
Ownership Overview
7.98% Insiders
29.90% Mutual Funds
0.40% Other Institutional Investors
47.98% Public Companies and Individual Investors